Tirzepatide

Tirzepatide (brand name Mounjaro for T2D, Zepbound for obesity) is a once-weekly subcutaneous injectable medication developed by Eli Lilly and Company. It is a 39-amino-acid synthetic peptide that acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors — a mechanism sometimes called a “twincretin.” The FDA approved it for Type 2 diabetes in May 2022, based on the SURPASS Phase 3 clinical trial programme of six trials.

The dual receptor mechanism distinguishes tirzepatide from earlier GLP-1 receptor agonists such as semaglutide and dulaglutide. Clinical evidence from the SURPASS programme (SURPASS-1 through SURPASS-6) consistently shows greater HbA1c reductions and greater weight loss than comparator GLP-1 receptor agonists and basal insulin regimens, in a dose-dependent fashion at 5 mg, 10 mg, and 15 mg weekly doses. All trials were funded by Eli Lilly and many principal investigators declared financial relationships with the manufacturer.

Tirzepatide is dosed once weekly by subcutaneous injection, starting at 2.5 mg and escalating by 2.5 mg every four weeks to a target maintenance dose (5, 10, or 15 mg). This titration schedule is designed to reduce gastrointestinal side effects, which are the most commonly reported adverse events. The most frequent GI events — nausea, diarrhoea, and vomiting — occurred primarily during dose escalation and were generally mild to moderate in severity.

A post-hoc analysis of SURPASS-4 (in T2D patients with high cardiovascular risk) found that tirzepatide slowed eGFR decline and reduced urinary albumin-to-creatinine ratio (UACR) compared with insulin glargine. However, this was a post-hoc analysis, not a pre-specified kidney outcomes trial. No dedicated powered renal outcomes trial for tirzepatide existed as of late 2024. The FDA label includes a warning about medullary thyroid carcinoma risk (as with GLP-1 class drugs) and contraindication in personal or family history of MEN2 or MTC; evidence in humans is unclear.

Ontology Tirzepatide [studied_in] SURPASS Clinical Trial Programme Tirzepatide [studied_in] SURPASS-1 Tirzepatide [studied_in] SURPASS-2 Tirzepatide [studied_in] SURPASS-4 Tirzepatide [studied_in] SURPASS-6 Tirzepatide [relates] Type 2 Diabetes Tirzepatide [relates] HbA1c Reduction Tirzepatide [relates] Insulin-Use Reduction Tirzepatide [relates] Kidney Outcomes Tirzepatide [relates] GIP Receptor Agonism Tirzepatide [relates] GLP-1 Receptor Agonism Tirzepatide [compared_against] Semaglutide Tirzepatide [compared_against] Insulin Glargine Tirzepatide [compared_against] Insulin Degludec Tirzepatide [compared_against] Insulin Lispro

Key Claims

• Claim: Tirzepatide meaningfully reduces HbA1c in T2D

  • Evidence status: Confirmed — consistent across all 6 SURPASS trials; HbA1c reductions of 1.87%–2.58% (monotherapy or vs insulin) in Phase 3 RCTs
  • Source: SURPASS-1 (Lancet 2021), SURPASS-2 (NEJM 2021), SURPASS-4 (Lancet 2021), SURPASS-6 (JAMA 2023)

• Claim: Tirzepatide reduces insulin use or delays insulin initiation

  • Evidence status: Confirmed for delaying prandial insulin intensification (SURPASS-3/4/6); allows basal insulin dose reduction in some patients
  • Source: SURPASS-3 (Lancet 2021), SURPASS-6 (JAMA 2023)

• Claim: Tirzepatide protects kidney function / slows CKD progression

  • Evidence status: Mixed — SURPASS-4 post-hoc shows reduced eGFR decline and UACR; no dedicated kidney outcomes RCT exists; confounding by weight loss and blood pressure reduction possible
  • Source: Heerspink et al., Lancet Diabetes Endocrinol 2022 (PMID 36152639)

• Claim: Tirzepatide improves blood circulation

  • Evidence status: Alleged — no direct clinical evidence; indirect via cardiovascular risk factor reduction (BP, weight, HbA1c); SURPASS-4 MACE-4 not increased (HR 0.74, CI 0.51–1.08) but trial not powered for CV outcomes
  • Source: SURPASS-4 (PMID 34672967)

• Claim: Tirzepatide causes risk of thyroid tumours

  • Evidence status: Weak in humans — FDA label carries class warning based on rodent data; human cases not established
  • Source: FDA prescribing information 2022

Connections

• SURPASS Clinical Trial Programme — studied_in, [2019–2023], source: PMID 34186022, 34170647, 34672967, 37786396
• HbA1c Reduction — associated_with, [2021–2023], source: PMID 35579691
• Insulin-Use Reduction — associated_with, [2021–2023], source: PMID 37786396, 34672967
• Kidney Outcomes — associated_with (post-hoc), [2022], source: PMID 36152639
• Semaglutide — compared_against, [2021], source: PMID 34170647
• Insulin Glargine — compared_against, [2021–2022], source: PMID 34672967
• Nausea and Vomiting Risk — warns_about, [2022], source: FDA label
• Thyroid Carcinoma Warning — warns_about, [2022], source: FDA label

Sources

• SURPASS-1 (Lancet 2021)
• SURPASS-2 vs semaglutide (NEJM 2021)
• SURPASS-4 vs glargine/CV risk (Lancet 2021)
• SURPASS-6 vs insulin lispro (JAMA 2023)
• Systematic review and meta-analysis (Diabetologia 2022)
• SURPASS-4 kidney outcomes post-hoc (Lancet Diabetes Endocrinol 2022)
• FDA prescribing information (Mounjaro 2022)